CONECTA

At a glance

• Editor score
  7.5 / 10
• Pricing
  Pricing on request
• Best for
  Enterprise teams tackling difficult protein targets
• Free plan
  No
• Target identification
  Yes
• Founded
  2019 · Cambridge, Massachusetts, United States
• Facts checked
  4 Oct 2026

• Where it wins

  • Searches a collection of more than 3 billion compounds
  • Supports targets without known binding pockets and multiple mechanisms
  • Applies more than 60 predictive drug-property models

• Where it doesn't

  • Pricing is contact-sales rather than publicly stated
  • No free plan is offered
  • The platform is proprietary, not open source

Our verdict on CONECTA

For enterprise drug-discovery teams seeking small-molecule candidates against difficult protein targets, CONECTA applies AI to a collection of more than 3 billion compounds. Montai Therapeutics describes its approach as biology-first and mechanism-agnostic: teams specify desired activity profiles, and the platform searches for chemistry that may match. Its scope spans target identification and molecule design, with a focus on chronic inflammatory and immunology diseases. The approach may suit programs where conventional target selection is constrained by the absence of a known binding pocket; it is less suited to buyers seeking a public self-serve product or a narrowly defined repurposing tool.

The standout capability is the breadth of target and mechanism exploration. CONECTA supports work on complex proteins without known binding pockets and can explore covalent binding, allosteric modulation, molecular glues, and protein-protein interaction inhibition. Multimodal foundation models map chemical space to biological pathways, while more than 60 predictive drug-property models contribute to candidate discovery and advancement. The platform also supports multiple distinct candidates, which can help teams explore alternatives within a program rather than focusing on a single compound. These capabilities make it relevant to discovery efforts that need to connect diverse chemistry with biological activity across less conventional target types.

CONECTA is a proprietary platform sold through a contact-sales model, so buyers should expect a vendor-led commercial conversation rather than selecting a published plan. Montai’s description places biology, chemistry, and drug development together in the discovery process, but the product is best evaluated by teams that can align those functions around candidate advancement. Enterprise groups with difficult targets and interest in multiple mechanisms are the clearest fit. Teams that need transparent published pricing, a free tier, or open-source software should consider alternatives; the product is not presented as a public self-service option.

Your product? Our editors can test CONECTA in depth and publish a review, labelled as paid · from $99/mo →

CONECTA pricing

CONECTA fact sheet

Alternatives to CONECTA

• ABAmazon Bio DiscoveryA cloud workflow for designing, ranking, and testing antibody candidates.9.3
• PPharma.AIA broad discovery suite spanning target research, molecule design and clinical-trial prediction.8.8
• RRecursionA broad discovery suite for teams connecting computational models with lab experiments.8.7

See all CONECTA alternatives →

Featured on iTechGuides

CONECTA is listed in our AI Drug Discovery Software directory. Add the badge to your site — it links back to this page.

<a href="https://www.itechguides.com/products/conecta/"><img src="https://www.itechguides.com/best/badge/conecta.svg" alt="Featured on iTechGuides" width="230" height="46"></a>

Reviewed by iTechGuides Editors · Editorial team · Updated Oct 2026

Advertiser disclosure: iTechGuides is reader-supported. Vendors can pay for top positions in our rankings and for a place on other products' pages, and we may earn a commission when you click some links. How we rank.

Last updated 21 Oct 2026 · How we research and update